HC Wainwright Issues Positive Forecast for Avadel Pharmaceuticals (NASDAQ:AVDL) Stock Price

Key Points

• HC Wainwright has raised the price target for Avadel Pharmaceuticals from $24.00 to $36.00, indicating a potential upside of 140.16% from the stock's previous close.
• The company reported $0.10 earnings per share for the last quarter, surpassing the consensus estimate of $0.02, with a revenue growth of 64.1% year-over-year.
• Avadel Pharmaceuticals currently holds an average rating of "Buy," with a consensus price target of $20.86 from various analysts.

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Free Report) had its price objective upped by analysts at HC Wainwright from $24.00 to $36.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. HC Wainwright's price objective suggests a potential upside of 126.84% from the company's current price. HC Wainwright also issued estimates for Avadel Pharmaceuticals' Q1 2026 earnings at $0.17 EPS, Q2 2026 earnings at $0.19 EPS and Q4 2026 earnings at $0.26 EPS.

AVDL has been the topic of a number of other research reports. Wall Street Zen raised Avadel Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 9th. UBS Group raised their price target on shares of Avadel Pharmaceuticals from $13.00 to $20.00 and gave the stock a "buy" rating in a research note on Thursday, August 21st. Lifesci Capital raised shares of Avadel Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, September 3rd. Needham & Company LLC reissued a "buy" rating and set a $19.00 price objective on shares of Avadel Pharmaceuticals in a research note on Thursday, May 8th. Finally, Wells Fargo & Company raised shares of Avadel Pharmaceuticals to a "hold" rating in a research note on Wednesday, September 3rd. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Avadel Pharmaceuticals has an average rating of "Buy" and an average price target of $20.86.

Avadel Pharmaceuticals Price Performance

AVDL traded up $0.28 during midday trading on Friday, reaching $15.87. 705,987 shares of the company's stock were exchanged, compared to its average volume of 1,356,828. The business's 50-day moving average price is $12.26 and its 200 day moving average price is $9.85. The stock has a market capitalization of $1.54 billion, a PE ratio of -528.17 and a beta of 1.58. Avadel Pharmaceuticals has a 1-year low of $6.38 and a 1-year high of $16.66.

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.08. The firm had revenue of $68.13 million during the quarter, compared to the consensus estimate of $60.28 million. Avadel Pharmaceuticals had a negative return on equity of 3.73% and a negative net margin of 1.32%.The company's quarterly revenue was up 64.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.14) EPS. Avadel Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, analysts expect that Avadel Pharmaceuticals will post -0.51 EPS for the current fiscal year.

Institutional Trading of Avadel Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Tower Research Capital LLC TRC raised its holdings in Avadel Pharmaceuticals by 217.5% in the second quarter. Tower Research Capital LLC TRC now owns 8,795 shares of the company's stock valued at $78,000 after buying an additional 6,025 shares during the period. Krensavage Asset Management LLC increased its position in shares of Avadel Pharmaceuticals by 0.9% in the second quarter. Krensavage Asset Management LLC now owns 958,877 shares of the company's stock worth $8,486,000 after acquiring an additional 8,877 shares in the last quarter. MML Investors Services LLC raised its stake in shares of Avadel Pharmaceuticals by 6.7% in the 2nd quarter. MML Investors Services LLC now owns 207,378 shares of the company's stock valued at $1,835,000 after acquiring an additional 13,072 shares during the period. Man Group plc lifted its holdings in shares of Avadel Pharmaceuticals by 101.3% during the 2nd quarter. Man Group plc now owns 57,931 shares of the company's stock valued at $513,000 after acquiring an additional 29,149 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Avadel Pharmaceuticals by 30.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 22,823 shares of the company's stock valued at $202,000 after acquiring an additional 5,372 shares in the last quarter. Institutional investors and hedge funds own 69.19% of the company's stock.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.